Bioscience

Cardiovascular BioTherapeutics, Inc. opens Florida and Arizona Sites for Its ACORD Phase II heart trial

February 24, 2009

By Flinn Foundation

[Source: Biospace.com/PRNewswire-FirstCall] — CardioVascular BioTherapeutics, Inc. announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease. The sites are Florida Hospital/Cardiovascular Institute – Orlando Florida and Chandler Regional Medical Center and Mercy Gilbert Medical Center – Phoenix Arizona metropolitan area.

For more information click here.